← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Lixisenatide

FDA approved · Rx

GLP-1 receptor agonist

Also known as: Adlyxin, Soliqua 100/33, Lyxumia, ZP10A peptide, ZP 10, AVE0010, AQVE-10010, AVE 0010

Evidence score
95/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 76 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Lixisenatide is a synthetic peptide that mimics the gut hormone GLP-1, derived from exendin-4. It activates GLP-1 receptors, which increases glucose-dependent insulin release, lowers glucagon, and slows stomach emptying, with a notable effect on after-meal blood sugar.

What the evidence shows

Automatic summaryHuman trials

Lixisenatide is FDA approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes, marketed as Adlyxin and in combination with insulin glargine as Soliqua 100/33. It has been studied in about 75 registered human trials up to Phase 4, and a large cardiovascular outcomes trial found it neither increased nor reduced major cardiovascular events.

Key facts

Molecular formula
C215H347N61O65S
Molecular weight
4858 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

76registered studies
Phase 4most advanced phase
58completed (sample)
2recruiting (sample)

GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

Phase 3CompletedNCT00707031

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

Phase 3CompletedNCT02787551

A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus

Phase 4CompletedNCT06716424

iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

Phase 3CompletedNCT05413369

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

702papers referencing Lixisenatide

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

N Engl J Med2015

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Lancet Diabetes Endocrinol2019

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.

Mol Metab2021

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.

Nat Rev Endocrinol2012

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.